Ureter Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
- $ 2000
- May 2024
- 150 pages
Magrolimab is under development for the treatment of Hodgkin lymphoma., [...] previously untreated, relapsed or refractory acute myelocytic leukemia and myelodysplastic syndrome, solid tumor, relapsed/refractory multiple myeloma, recurrent head and neck squamous cell carcinoma, pancreatic ductal adenocarcinoma, urethral cancer, metastatic urothelial cancer,metastatic small cell lung cancer and metastatic non-small cell lung cancer, ureter cancer, breast cancer, colorectal cancer, epithelial ovarian cancer, fallopian tube cancer, peritoneal cancer, head and neck cancer, ovarian, AML, NHL, myelodysplastic syndrome, relapsed and refractory B-cell non-Hodgkin's lymphoma, triple negative breast cancer, indolent lymphoma, metastatic transitional (urothelial) tract cancer, bladder cancer, marginal zone or follicular lymphoma, malignant primary brain tumor, metastatic colorectal cancer and atherosclerosis. [...] It was also under development fordiffuse large B-cell lymphoma,cutaneous T-cell lymphoma.